12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This was an open-label, extension trial designed to evaluate the long-term safety over 12
months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia.
Patients recruited into this trial were those who had successfully completed the double-blind
study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they
received during the double-blind study.